| Methods |
Multicentre, double‐blind, placebo‐controlled
Randomisation technique not stated, stratified by thrombotic and embolic stroke
ITT analysis |
| Participants |
USA, 5 centres
T: 43, C: 37
Mean age: 65 years
49 male, 31 female
Inclusion: IS
100% CT pre‐entry
Enrolment within 24 hours |
| Interventions |
T: PGI2 (epoprostenol sodium, Upjohn Co, USA, and Wellcome, UK) iv infusion started at 1 ng/kg/min increased every 30 minutes until maximum rate of 10 ng/kg/min; infusion for 72 hours with gradual reduction of dose during last 12 hours
C: solvent
Rx: 3 days |
| Outcomes |
Death at 4 weeks
(Neurological impairment assessed using Turnhill score at entry, day 3, weeks 1, 2 + 4)
Method of BP measurement not known |
| Notes |
Ex: stupor, coma, psychiatric disorder, clinical intracranial hypertension, organ or systemic disease, bleeding risk, heparin
Further information unavailable because original data discarded
Data from unpublished manuscript |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Probably done |
| Allocation concealment? |
Unclear risk |
Unclear from the publication |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Unclear risk |
Unclear from the publication |
